| Project/Area Number |
26461580
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小島 勢二 名古屋大学, 医学系研究科, 名誉教授 (20313992)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KIMURA Hiroshi 名古屋大学, 大学院医学系研究科, 教授 (30303621)
MIZUNO Masaaki 名古屋大学, 医学部附属病院, 病院教授 (70283439)
|
|---|
| Research Collaborator |
LEEN Ann 米国ベイラー医科大学, Pediatrics-Hem-Onc Cell & Gene, 助教
SAJI Hiroo HLA研究所, 所長
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | ＥＢウイルス / 造血幹細胞移植 / ＣＴＬ / 小児血液学 / EBウイルス / CTL / ウイルス / 造血細胞移植 / 細胞療法 |
|---|
| Outline of Final Research Achievements |
We analyzed the relation of EBV reactivation and Anti-thymocyte globulin (ATG) blood concentration in 90 cases and revealed that EBV reactivation was significantly more in high ATG concentration group. We could successfully developed EBV specific CTLs from 3rd party donors using not only HLA A2402/A0201 peptides but also HLA-A11 restricted peptides. We started the phase 1 clinical trial of EBV specific CTL therapy from the 3rd party donors.
|
